Two Sigma Advisers LP Increases Stock Holdings in Progyny, Inc. (NASDAQ:PGNY)

Two Sigma Advisers LP boosted its position in Progyny, Inc. (NASDAQ:PGNY - Free Report) by 83.8% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 266,100 shares of the company's stock after buying an additional 121,300 shares during the period. Two Sigma Advisers LP owned approximately 0.31% of Progyny worth $4,590,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently bought and sold shares of PGNY. River Road Asset Management LLC purchased a new stake in Progyny in the 4th quarter worth approximately $25,529,000. Pacer Advisors Inc. boosted its position in Progyny by 47.5% in the 4th quarter. Pacer Advisors Inc. now owns 3,676,200 shares of the company's stock worth $63,414,000 after purchasing an additional 1,183,558 shares in the last quarter. Barclays PLC boosted its position in Progyny by 95.7% in the 4th quarter. Barclays PLC now owns 1,382,205 shares of the company's stock worth $23,843,000 after purchasing an additional 676,048 shares in the last quarter. D. E. Shaw & Co. Inc. purchased a new stake in Progyny in the 4th quarter worth approximately $11,265,000. Finally, BNP Paribas Financial Markets purchased a new stake in Progyny in the 4th quarter worth approximately $10,557,000. Hedge funds and other institutional investors own 94.93% of the company's stock.

Analyst Upgrades and Downgrades

PGNY has been the topic of several recent research reports. BTIG Research upgraded Progyny from a "neutral" rating to a "buy" rating and set a $28.00 price objective on the stock in a research report on Monday, March 31st. Canaccord Genuity Group reduced their price objective on Progyny from $23.00 to $21.00 and set a "hold" rating for the company in a research note on Monday, May 12th. JPMorgan Chase & Co. increased their price objective on Progyny from $17.00 to $23.00 and gave the company a "neutral" rating in a research note on Tuesday, January 28th. Finally, Bank of America increased their price objective on Progyny from $21.00 to $25.00 and gave the company a "buy" rating in a research note on Tuesday, February 11th. Seven analysts have rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat.com, Progyny presently has a consensus rating of "Hold" and a consensus price target of $23.45.

Progyny Trading Up 3.2%

Shares of Progyny stock traded up $0.66 during mid-day trading on Wednesday, hitting $21.25. 1,177,219 shares of the stock were exchanged, compared to its average volume of 1,708,217. Progyny, Inc. has a twelve month low of $13.39 and a twelve month high of $30.42. The stock has a market capitalization of $1.82 billion, a price-to-earnings ratio of 36.64, a price-to-earnings-growth ratio of 2.39 and a beta of 1.37. The company has a 50-day simple moving average of $22.11 and a 200 day simple moving average of $20.01.

Progyny (NASDAQ:PGNY - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The company reported $0.17 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.45 by ($0.28). Progyny had a return on equity of 11.36% and a net margin of 5.03%. The firm had revenue of $324.04 million for the quarter, compared to analyst estimates of $307.86 million. During the same period in the prior year, the business earned $0.17 earnings per share. Progyny's revenue for the quarter was up 16.5% on a year-over-year basis. Equities research analysts forecast that Progyny, Inc. will post 0.6 earnings per share for the current fiscal year.

Progyny Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.